Silver Book Fact

Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.

Ettinger B, Black D, Mitlak B, Knickerbocker R, et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999; 282(7): 637-45. http://jama.ama-assn.org/cgi/content/abstract/282/7/637?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Reduction+of+Vertebral+Fracture+Risk+in+Postmenopausal+Women+with+Osteoporosis+Treated+with+Raloxifene&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial
Publication
JAMA
Publication Date
1999
Authors
Ettinger B, Black D, Mitlak B, Knickerbocker R, et al.
Volume & Issue
Volume 282, Issue 7
Pages
637-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…